The medicines which have received Good Manufacturing Practice (“GMP”) certifications issued by the State Food and Drug Administration of the PRC are in the following dosage forms: large volume injections, small volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines and granulated medicines. The Group also received the GMP certification for health food in capsules from the Department of Health of Jiangsu Province.
Beijing Tide Pharmaceutical Co. Ltd. (“Beijing Tide”), an associate of the Group, has obtained the renewed GMP certification for foreign pharmaceutical company from the Public Welfare and Health Ministry of Japan in December 2012. Thus, any Japanese pharmaceutical enterprises can assign the manufacturing of aseptic pharmaceutical products (products that are under research and those products already launched in the domestic market within Japan) to Beijing Tide for export to Japan.
In September 2011, CT Tianqing received the first certificate of the new edition GMP (Certificate No. CN20110001) issued by the State Food and Drug Administration of the PRC for its small volume parenteral solution (injection) dosage.
High and New Technology Enterprises
The Group's several principal subsidiaries, all of which have been designated “High and New Technology Enterprises”:
Chia Tai – Tianqing Pharmaceutical Holdings Co. Ltd. (“CT Tianqing”)
Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTT”)
Beijing Chia Tai Green Continent Pharmaceutical Co. Ltd. (“CTGP”)
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (“Jiangsu Fenghai”)
Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. (“Jiangsu Qingjiang”)
Qingdao Chia Tai Haier Pharmaceutical Co., Ltd. (“Qingdao Haier”)
Shanghai Tongyong Pharmaceutical Co., Ltd. (“Shanghai Tongyong”)
Lianyungang Runzhong Pharmaceutical Co., Ltd. (“LYG Runzhong”)
The Company ranked 447, 410 and 442 of "China's Top 500 Companies" by Fortune China in 2015, 2016 and 2017 respectively.
The Company has been included on Forbes Asia's "Fabulous 50" list for 2016 among Asia Pacific's biggest publicly-traded companies on 25 August, 2016.
The Company has been a constituent of the MSCI Global Standard Indices’ MSCI China Index since 1 June, 2013.
The Company has been selected as a constituent of the Hang Seng Composite Industry Index – Consumer Goods and Hang Seng Composite Small Cap Index since 8 March, 2010.
Designated “2011 Most Valuable Investment Enterprise of the PRC Pharmaceutical Enterprises” by PRC Pharmaceutical Industry Information Centre
NJCTT, Jiangsu Qingjiang and Jiangsu Fenghai
“Engineering Technological Research Centre for treating tumors and cardiocerebral phytochemistry injections of Jiangsu Province”
“Orthopedic Medicines Engineering Technological Research Centre”
“Engineering Technological Research Centre for Anorectal Nutritious Medicines” by The Science and Technology Committee of Jiangsu Province
CT Tianqing Research Center
“Postdoctoral Research and Development Institute” by the Ministry of Personnel of the PRC the only “New Hepatitis Medicine Research Center” in China